F2R and COVID-19: Several drugs, including antivirals and antimalarial/parasiticide drugs, have been tested in clinical trials, but none of them have been certified to be a precise therapeutics yet.5 Here we will review some insights with regards to the pathogenesis of COVID-19 in severe cases and consider the protease-activated receptor 1 (PAR1) as a potential therapeutic target.